Gene Techno Science Co., Ltd. is primarily engaged in the development of biopharmaceuticals including biosimilars and new drugs. The biopharmaceuticals are medicines based on the mechanism of living body, can not be achieved with existing low molecular medicines, and are produced by biotechnology including genetic engineering. The biopharmaceuticals business is engaged in the research and development of biopharmaceuticals. The biosimilars and new drugs business is engaged in research and development of biosimilars and new drugs, as well launching regenerative medicine field as new business. It also has a pipeline with multiple developed products.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.